Related Experiment Video
Updated: May 8, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Evaluating and adjusting for premature censoring of progression-free survival
Mark Rothmann1, Kallappa Koti, Kyung Yul Lee
1Division of Biometrics 5, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland 20993-0002, USA. Mark.Rothmann@fda.hhs.gov
Abstract:
The intent-to-treat principle, grouping subjects as they were randomized and following all subjects to the endpoint or the end of study, allows valid statistical comparisons. Progression-free survival (PFS) has been used as a decision-making endpoint in oncology. It can be difficult to have a meaningful intent-to-treat analysis of PFS as some studies have extensive loss to follow-up for PFS. In the analysis, subjects lost to follow-up for PFS have their PFS times censored, with the censoring treated as noninformative. We use remaining overall survival to investigate whether premature censoring for PFS is informative and the potential bias in treating such censoring as noninformative.
Related Concept Videos
Censoring Survival Data
Kaplan-Meier Approach
Assumptions of Survival Analysis
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...